Southern Capital Advisors LLC Acquires Shares of 3,107 Johnson & Johnson (NYSE:JNJ)

Southern Capital Advisors LLC acquired a new stake in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 3,107 shares of the company’s stock, valued at approximately $532,000.

Several other hedge funds and other institutional investors also recently modified their holdings of JNJ. Mercer Global Advisors Inc. ADV raised its stake in shares of Johnson & Johnson by 4.5% in the fourth quarter. Mercer Global Advisors Inc. ADV now owns 344,918 shares of the company’s stock worth $59,005,000 after acquiring an additional 14,872 shares during the last quarter. Revolve Wealth Partners LLC acquired a new position in shares of Johnson & Johnson during the fourth quarter valued at $2,574,000. Wealth Dimensions Group Ltd. lifted its stake in shares of Johnson & Johnson by 1.3% during the fourth quarter. Wealth Dimensions Group Ltd. now owns 15,953 shares of the company’s stock valued at $2,729,000 after acquiring an additional 197 shares during the period. Kentucky Retirement Systems Insurance Trust Fund lifted its stake in Johnson & Johnson by 1.9% in the fourth quarter. Kentucky Retirement Systems Insurance Trust Fund now owns 69,688 shares of the company’s stock valued at $11,922,000 after buying an additional 1,275 shares during the period. Finally, Hendershot Investments Inc. lifted its stake in Johnson & Johnson by 30.6% in the fourth quarter. Hendershot Investments Inc. now owns 138,680 shares of the company’s stock valued at $23,724,000 after buying an additional 32,487 shares during the period. 67.84% of the stock is owned by institutional investors.

In related news, VP Thibaut Mongon sold 23,681 shares of Johnson & Johnson stock in a transaction that occurred on Thursday, March 17th. The stock was sold at an average price of $176.25, for a total transaction of $4,173,776.25. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 0.35% of the company’s stock.

JNJ stock traded up $6.04 during mid-day trading on Tuesday, reaching $183.70. The company had a trading volume of 681,286 shares, compared to its average volume of 7,890,662. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.35 and a quick ratio of 1.12. The stock has a 50 day simple moving average of $172.50 and a two-hundred day simple moving average of $168.01. The company has a market capitalization of $483.00 billion, a price-to-earnings ratio of 22.75, a PEG ratio of 2.71 and a beta of 0.72. Johnson & Johnson has a 52 week low of $155.72 and a 52 week high of $184.20.

Johnson & Johnson (NYSE:JNJ – Get Rating) last released its quarterly earnings data on Tuesday, April 19th. The company reported $2.67 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $2.61 by $0.06. Johnson & Johnson had a return on equity of 37.46% and a net margin of 22.26%. The company had revenue of $23.43 billion during the quarter, compared to analysts’ expectations of $23.62 billion. During the same period last year, the firm posted $2.59 earnings per share. The business’s revenue was up 5.0% on a year-over-year basis. On average, equities analysts predict that Johnson & Johnson will post 10.48 EPS for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 7th. Stockholders of record on Tuesday, May 24th will be given a $1.13 dividend. This represents a $4.52 dividend on an annualized basis and a dividend yield of 2.46%. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.06. The ex-dividend date is Monday, May 23rd. Johnson & Johnson’s dividend payout ratio (DPR) is presently 54.29%.

Several equities analysts have weighed in on JNJ shares. The Goldman Sachs Group increased their target price on Johnson & Johnson from $163.00 to $181.00 and gave the company a “neutral” rating in a research note on Tuesday, April 12th. Sanford C. Bernstein lowered Johnson & Johnson from an “outperform” rating to a “market perform” rating and increased their target price for the company from $180.00 to $183.00 in a research note on Wednesday, March 16th. Morgan Stanley decreased their price objective on Johnson & Johnson from $175.00 to $173.00 and set an “equal weight” rating for the company in a report on Wednesday, April 6th. StockNews.com assumed coverage on Johnson & Johnson in a report on Thursday, March 31st. They set a “strong-buy” rating for the company. Finally, Raymond James increased their price objective on Johnson & Johnson from $185.00 to $195.00 and gave the stock an “outperform” rating in a report on Thursday, April 14th. Four analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $184.57.

About Johnson & Johnson (Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets.

Read More